LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, announced its participation in the BTIG 4th Annual Ophthalmology Day.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, announced its participation in the BTIG 4th Annual Ophthalmology Day. CEO Nick Curtis will engage in a fireside chat on December 2, 2024, at 2 p.m. ET. The company's management team will also conduct one-on-one meetings with institutional investors. The event is exclusively for current and prospective BTIG clients, who must contact their BTIG representative to access the live event.
Details
News Market Reaction – LNSR
The recorded move for LNSR in the trading session of this news was +1.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.